Inotropes in Patients with Advanced Heart Failure

Masarone, Daniele; Melillo, Enrico; Gravino, Rita; Errigo, Vittoria; Martucci, Maria; Caiazzo, Anna; Petraio, Andrea; Pölzl, Gerhard; Pacileo, Giuseppe

doi:10.1016/j.hfc.2021.05.004

Cited by 17 publications

(12 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another strategy used in patients with advanced heart failure is the periodic infusion of levosimendan ( 19 ), which can lead to an improvement in the hemodynamic profile ( 20 ) and quality of life as well as reduction of acutely decompensated heart failure episodes in patients with advanced HFrEF ( 21 ). Pulsed levosimendan infusion can be performed at fixed intervals or by assessing changes in hemodynamic parameters ( 22 ), leading to a clear clinical benefit in both cases.…”

Section: Discussionmentioning

confidence: 99%

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Masarone

Petraio

Fiorentino³

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Cardiac contractility modulation (CCM) is a novel device-based therapy in patients with heart failure with reduced ejection fraction (HFrEF). In randomized clinical trials and real-life studies, CCM has been shown to improve exercise tolerance and quality of life, reverse left ventricular remodeling and reduce hospitalization in patients with HFrEF. In this case report, we describe for the first time the use of CCM as a “bridge to transplant” in a young obese patient with advanced heart failure due to non-ischemic dilated cardiomyopathy. The patient had a poor quality of life and frequent heart failure-related hospitalizations despite the optimal medical therapy and, due to obesity, a suitable heart donor was unlikely to be identified in the short term and due to severe obesity risk of complications after implantation of a left ventricular assist device (LVAD) was very high.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Masarone

Petraio

Fiorentino³

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In previous studies, repeated use at fortnightly intervals was shown to be safe as well as effective in advanced HF cases, relieving symptoms, reducing hospitalizations, and improving quality of life. 4 In one of…”

Section: Discussionmentioning

confidence: 99%

Intermittent Inotrope Infusion Associated with Peritoneal Dialysis for Management of Advanced Heart Failure Secondary to Cardiac Amyloidosis

Otaviano¹,

Eto²,

Schwartzmann³

2022

ABC: Heart Failure &Amp; Cardiomyopathy

View full text Add to dashboard Cite

“…Recently, repetitive shorter infusions of levosimendan in ambulatory settings have been proposed as a therapeutic option also in patients with advanced chronic HF, with evidence for preservation of health-related quality of life and reduction in hospitalizations. 5–7…”

Section: Introductionmentioning

confidence: 99%

Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study

Masarone

Melillo

Errigo

et al. 2022

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

Infusions of levosimendan delivered in ambulatory/ outpatient settings have been shown to improve quality of life and reduce hospitalizations in patients with advanced heart failure (HF). The aim of this pilot study was to evaluate the effects of ambulatory infusion of levosimendan on echocardiographic markers of perfusion, congestion, and cardiovascular efficiency. Thirty patients with diagnosed advanced HF underwent ambulatorial infusion of levosimendan at a total dose of 6.25 mg as a part of a repetitive biweekly treatment strategy with the inotrope. Standardized transthoracic echocardiography and Doppler examinations, were performed 1 hour before and 48 hours after completion of ambulatory infusion. At 48 hours after ambulatory infusion of levosimendan, a significant increase in the stroke volume (37.47 6 12.38 mL/beat vs. 45.47 6 14.48 mL/beat; P , 0.05) and cardiac output (2.64 6 0.66 L/min vs. 3.26 6 0.57 L/min; P , 0.05) occurred. Significant postreductions versus prereductions were also recorded in left atrial pressure (27.37

show abstract

Inotropes in Patients with Advanced Heart Failure

Cited by 17 publications

References 78 publications

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Use of Cardiac Contractility Modulation as Bridge to Transplant in an Obese Patient With Advanced Heart Failure: A Case Report

Intermittent Inotrope Infusion Associated with Peritoneal Dialysis for Management of Advanced Heart Failure Secondary to Cardiac Amyloidosis

Hemodynamic Effects of Levosimendan in Outpatients With Advanced Heart Failure: An Echocardiographic Pilot Study

Contact Info

Product

Resources

About